Persevere Therapeutics
Chesterbrook, US · Founded 2025 · Delaware corporation
Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
Founders & leadership
GB
Greg BoschinExecutive
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2026
▶$1.6MraisedMar 2026 · 12 investors · OtherRule 506(b)
▶$1.6MraisedMar 2026 · 12 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Greg BoschExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.6M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Sapience Therapeutics4 shared keywordsSapience Therapeutics is a clinical-stage biotechnology company developing peptide-based cancer therapies that target traditionally undruggable oncogenic proteins and protein-protein interactions. Its pipeline includes SPEAR peptides that act inside cancer cells and SPARC peptides that act on the outside, with lead candidates lucicebtide (ST101) and ST316 in Phase 2 oncology trials.
Jupiter Bioventures4 shared keywordsJupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas. The company is led by a team of experienced scientists and executives with a track record of creating approved drugs and founding successful biotech companies.
Coya Therapeutics3 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
C4 Therapeutics3 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies competing with Persevere Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Persevere Therapeutics do?
- Persevere Therapeutics is a clinical-stage oncology company developing misetionamide, a small molecule asset with a novel dual-target mechanism that inhibits cancer cell energy metabolism and proliferation. The company is advancing misetionamide through clinical trials for platinum-resistant ovarian cancer and other tumor types including pancreatic, melanoma, and colorectal cancers.
- How much funding has Persevere Therapeutics raised?
- Persevere Therapeutics has disclosed $1.6M raised across 1 round.
- Where is Persevere Therapeutics headquartered?
- Persevere Therapeutics is headquartered in Chesterbrook, US.